Gout drug shows promise for diabetic kidney protection in small trial

NCT ID NCT07177898

Completed Disease control Sponsor: Narowal Medical College Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study tested whether adding allopurinol (a gout medication) to standard lisinopril treatment could better protect kidneys in people with type 2 diabetes. 80 patients with normal uric acid levels were split into two groups: one received both drugs, the other lisinopril alone. Researchers tracked kidney function over a year to see if urine albumin levels rose, a sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: allopurinol and lisinopril
What this could lead to: If adding allopurinol works, it could offer a simple, low-cost way to help protect kidneys in people with type 2 diabetes.
What could go wrong: This is a small, single-center study with only 80 participants. Results may not apply to everyone, and the benefit might be small or not confirmed in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE (DKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE (DKD)

Contacts and locations

Locations

King Edward Medical University

Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.